<DOC>
	<DOCNO>NCT00909181</DOCNO>
	<brief_summary>The primary objective double-blind phase study compare effect two dos oxybutynin gel placebo gel . The objective open-label extension evaluate extend safety skin-irritation profile topically administer oxybutynin gel . The hypothesis topically administer oxybutynin gel decrease ( compare placebo ) number incontinence episode per week , average daily urinary frequency , urinary urgency ; increase average urinary void volume ; improve patient quality life .</brief_summary>
	<brief_title>Study Topically Administered Oxybutynin Gel Patients With Urge Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Urge</mesh_term>
	<mesh_term>Oxybutynin</mesh_term>
	<mesh_term>Mandelic Acids</mesh_term>
	<criteria>Overactive bladder ( OAB ) symptom urge and/or mixed UI predominance urge incontinence least 3 month Have history least 1 2 urge episode 8 void per day Incontinence predominantly stress , insensate , overflow nature , incontinence relate chronic illness , anatomical weakness/abnormalities concomitant medication PVR volume &gt; 200 mL relative PVR &gt; 50 % prevoid volume determine bladder ultrasound History urinary retention , gastric retention , uncontrollable narrowangle glaucoma , patient risk condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>